Indication
Details coming soon
Details coming soon
| Clinical Information | Administration Information |
|---|---|
|
Indication: Active immunisation against measles, mumps and rubella Age: Adult (19-49 years old) |
Dose: Subcutaneous Injection – 0.5 mL Note: Second dose may be administered 28 days apart; intramuscular or subcutaneous route mentioned for active immunization |
|
Indication: Active immunisation against measles, mumps and rubella Age: Adult (greater than 50 years old) |
Dose: Subcutaneous Injection – 0.5 mL Note: Administer 1 dose only; intramuscular or subcutaneous route mentioned for active immunization |
| Clinical Information | Administration Information |
|---|---|
|
Indication: Active immunisation against measles, mumps and rubella Age: 12-15 months |
Dose: Subcutaneous Injection – 0.5 mL Note: First dose |
|
Indication: Active immunisation against measles, mumps and rubella Age: 4-6 years |
Dose: Subcutaneous Injection – 0.5 mL Note: Second dose; may be administered during any visit provided that at least 4 weeks have elapsed since the first dose and that both doses are administered beginning at or after age 12 months |
| Drug Name | Risk Factors |
|---|---|
|
Immune globulins
|
May reduce the efficacy of vaccines
|
|
Tuberculin tests
|
May reduce the diagnostic effect
|
| Disease Name | Risk Factors |
|---|---|
|
Active untreated tuberculosis
|
Risk of severe complications
|
|
Blood dyscrasias
|
Reduced vaccine effectiveness
|
Details coming soon
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.